The major focus of this investigation was based upon our preliminary finding that KRAS mutated CRC cell presented a better candidacy for reovirus mediated oncolysis [13] and this is clinically relevant as the treatment options are currently limited for this cohort of CRC patients [18]. This evidence concerns the gene KRAS and colorectal carcinoma.